Recently, ReFine Biosciences, a leading company in the synthetic biology sector, announced the completion of a hundred-million-yuan Series C financing round. The round was led by a prominent investment firm, with continued participation from several existing shareholders. The proceeds will be primarily used to accelerate the commercialization of its core products, expand its global market presence, and further invest in the development of its synthetic biology platform technologies. ReFine Biosciences specializes in using synthetic biology to produce high-value natural compounds—such as flavors, nutraceuticals, and functional food ingredients—offering a green and sustainable alternative to traditional chemical manufacturing processes. The company has established an integrated technology platform covering strain engineering, fermentation optimization, and downstream purification, and has formed strategic partnerships with several global consumer goods leaders. This successful Series C round not only reflects strong investor confidence in the synthetic biology space but also marks a significant milestone in ReFine’s commercialization journey. Moving forward, the company aims to deepen the application of bio-manufacturing technologies across personal care, food, and pharmaceutical industries, contributing to a more sustainable and low-carbon global economy.
近日，合成生物学领域领先企业瑞芬生物（ReFine Biosciences）宣布完成亿元级C轮融资。本轮融资由知名投资机构领投，多家老股东持续跟投，资金将主要用于加速其核心产品的产业化落地、拓展全球市场布局，以及加强合成生物学平台技术的研发投入。瑞芬生物专注于利用合成生物学技术开发高附加值的天然产物，如香料、营养素和功能性食品成分，致力于以绿色、可持续的方式替代传统化工生产路径。公司已建成从菌株构建、发酵优化到分离纯化的完整技术平台，并与多家国际头部消费品企业建立了战略合作关系。此次C轮融资的成功，不仅体现了资本市场对合成生物学赛道的高度认可，也标志着瑞芬生物在商业化进程上迈入新阶段。未来，公司将继续推动生物制造技术在日化、食品及医药等领域的深度应用，助力全球绿色低碳转型。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/6926.html